Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004049785 | SCV002624629 | uncertain significance | not specified | 2023-05-14 | criteria provided, single submitter | clinical testing | The p.Q1244P variant (also known as c.3731A>C), located in coding exon 7 of the MLH3 gene, results from an A to C substitution at nucleotide position 3731. The glutamine at codon 1244 is replaced by proline, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003408234 | SCV004107838 | uncertain significance | MLH3-related disorder | 2023-08-10 | criteria provided, single submitter | clinical testing | The MLH3 c.3731A>C variant is predicted to result in the amino acid substitution p.Gln1244Pro. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.020% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/14-75498867-T-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Center for Genomic Medicine, |
RCV004049785 | SCV005090105 | uncertain significance | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing |